Please login to the form below

Not currently logged in
Email:
Password:

Marc Becker joins CRISPR Therapeutics

He becomes chief financial officer

CRISPR Therapeutics Marc BeckerCRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.

Becker brings over 20 years of commercial, operational and corporate finance expertise to the role, having held senior positions at BankBoston, Genzyme, KPMG and rEVO Biologics.

He joins the Switzerland-headquartered biopharmaceutical company from rEVO Biologics, where he served as its chief financial officer from 2012 until February this year.

While at rEVO, Becker was responsible for leading the finance department, directing the firm's market strategy and managing its governance.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Marc's extensive network and proven track record to establish internal controls will be vital as we continue to engage in key strategic ventures to support the discovery, development and commercialisation of new breakthrough therapeutics.”

Becker said: “I am excited to join the CRISPR Therapeutics leadership team as the company's growth accelerates with the introduction of strategic partnerships and ventures.

“Our technology is truly revolutionary and I'm delighted to be part of the team that will enable the development of life-changing medicines.”

21st March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics